Contraception
Volume 81, Issue 4 , Pages 336-342 , April 2010

Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques

  • Robert M. Brenner

      Affiliations

    • Division of Reproductive Sciences, Oregon National Primate Research Center, OHSU, Beaverton, OR 97006, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 503 690 5331; fax: +1 503 690 5532.
    • ,
  • Ov D. Slayden

      Affiliations

    • Division of Reproductive Sciences, Oregon National Primate Research Center, OHSU, Beaverton, OR 97006, USA
    • ,
  • Anita Nath

      Affiliations

    • Center for Biomedical Research, Population Council, New York, NY 10065, USA
    • ,
  • Y.Y. Tsong

      Affiliations

    • Center for Biomedical Research, Population Council, New York, NY 10065, USA
    • ,
  • Regine Sitruk-Ware

      Affiliations

    • Research and Development, Center for Biomedical Research, Population Council and The Rockefeller University, New York, NY 10065, USA

Received 8 September 2009 ,Revised 6 November 2009 ,Accepted 10 November 2009.

References 

  1. Brenner RM, Slayden OD. Progesterone receptor antagonists and the endometrial antiproliferative effect. Semin Reprod Med. 2005;23:74–81
  2. Chwalisz K, Brenner RM, Fuhrmann U, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators (PRMs) on the endometrium. Steroids. 2000;65:741–751
  3. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26:423–438
  4. Goodman AL, Hodgen GD. Progesterone receptor antagonists. In:  Adashi EY,  Rock JA,  Rosenwaks Z editor. Reproductive endocrinology, surgery, and technology, Chapter 27. Philadelphia: Lippincott-Raven Publishers; 1996;p. 548–558
  5. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmacological characterization of antiprogestins and progesterone receptor modulators (PRMs) with respect to PR-agonistic and -antagonistic activity. Steroids. 2000;65:713–723
  6. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol. 2002;188:111–123
  7. Hild SA, Reel JR, Hoffman LH, Blye RP. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod. 2000;15:822–829
  8. Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003;68:1013–1017
  9. Gainer E, Ulmann A. Pharmacologic properties of CDB (VA)-2914. Steroids. 2003;68:1005–1011
  10. Ortiz ME, Croxatto HB, Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Survey. 1996;51(Suppl):S42–S51
  11. McGavigan CJ, Cameron IT. The Mirena levonorgestrel system. Drugs Today (Barc). 2003;39:973–984
  12. Nayak NR, Slayden OD, Chwalisz K, Lehtinen M, Brenner RM. Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception. Contraception. 2007;75:S104–S111
  13. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92:3582–3589
  14. Slayden OD, Chwalisz K, Brenner RM. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod. 2001;16:1562–1574
  15. Slayden OD, Koji T, Brenner RM. Microwave stabilization enhances immunocytochemical detection of estrogen receptor in frozen sections of macaque oviduct. Endocrinology. 1995;136:4012–4021
  16. Petersen RG. Design and Analysis of Experiments. 66th ed.. New York: Marcel Dekker, Inc.; 1985;
  17. Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol. 2006;4(Suppl 1):S8
  18. Wolf JP, Hsiu JG, Anderson TL, Ulmann A, Baulieu EE, Hodgen GD. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen- stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril. 1989;52:1055–1060
  19. Slayden OD, Nayak NR, Burton KA, et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab. 2001;86:2668–2679
  20. Narvekar N, Cameron S, Critchley H, LIn S, Cheng L, Baird D. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab. 2004;89:2491–2497
  21. Brenner RM, Slayden OD, Nayak NR, Baird DT, Critchley HO. A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids. 2003;68:1033–1039
  22. Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction. 2002;124:167–172
  23. Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab. 2003;88:946–949
  24. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18:61–68
  25. Williams AR, Critchley HO, Osei J, Ingamells S, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22:1696–1704
  26. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–598
  27. Heikinheimo O, Vani S, Carpen O, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod. 2007;22:2515–2522

PII: S0010-7824(09)00488-0

doi: 10.1016/j.contraception.2009.11.004

Contraception
Volume 81, Issue 4 , Pages 336-342 , April 2010

Article Tools

* Image Usage & Resolution